This new drug may slow Alzheimer’s by a third

Experts are calling it a ‘turning point’ in the Alzheimer’s fight. Donanemab helps clear a protein that builds up in the brain. So Alzheimer’s sufferers can still manage daily tasks from shopping to answering the phone. Scientists enrolled 1,736 Alzheimer’s patients in a trial. Half of them received a monthly donanemab infusion. The others received a placebo. After 76 weeks, the drug had slowed the disease progression by 35% in early-stage sufferers.